Clinical trials: Allogeneic Disease
Acute Myeloid Leukemia
A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)
The purpose of this study was to compare relapse-free survival between participants with FLT3/ITD AML in first morphologic complete remission (CR1) who underwent hematopoietic stem cell transplant (HCT) and were randomized to…
- Trial name
- NCT02997202
- Testing
- gilteritinib
- Where
- 118 sites in United States, Australia and 14 more
- Volunteers
- 356 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the…
- Conditions
- Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant
- Trial name
- ALLELE (NCT03394365)
- Testing
- tabelecleucel
- Where
- 71 sites in United States, Australia and 7 more
- Volunteers
- 115 people
- Sponsor
- Pierre Fabre Medicament
Leukemia, Myeloid, Acute
A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML)
The purpose of this study is to define a safe dose of AC220 when given as maintenance therapy after treatment with an allogeneic stem cell transplant.
- Trial name
- NCT01468467
- Testing
- AC220
- Where
- 5 sites in United States
- Volunteers
- 13 people
- Sponsor
- Daiichi Sankyo
Non Hodgkin's Lymphoma, Large B-cell Lymphoma
Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)
SC262-101 is a Phase 1 study to evaluate SC262 safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.
- Trial name
- NCT06285422
- Testing
- SC262
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- Sana Biotechnology
Cancer, Malignancy
Allogeneic NKG2DL-targeting CAR γδ T Cells (CTM-N2D) in Advanced Cancers (ANGELICA)
CAR-T is a pioneering cancer treatment which has found success in some cancers. This treatment is made first by taking blood cells from the patient.
- Conditions
- Cancer, Malignancy, Refractory Cancer, Relapsed Cancer
- Trial name
- ANGELICA (NCT05302037)
- Testing
- Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells (CTM-N2D)
- Where
- Singapore
- Volunteers
- 12 people
- Sponsor
- CytoMed Therapeutics Pte Ltd
Graft-versus-host Disease (GVHD)
An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant
To provide ruxolitinib through an expanded access program for the treatment of graft-versus-host disease (GVHD) in United States to patients who are ineligible or unable to participate in any actively enrolling Incyte-sponsored…
- Trial name
- NCT03147742
- Testing
- Ruxolitinib
- Where
- 33 sites in United States
- Sponsor
- Incyte Corporation
Corticosteroid Refractory Acute Graft vs Host Disease
Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation
Assess the efficacy and safety of ruxolitinib compared to Best Available Therapy (BAT) in patients with corticosteroid-refractory acute graft vs. host disease (aGvHD) after allogeneic stem cell transplantation.
- Trial name
- REACH2 (NCT02913261)
- Testing
- Ruxolitinib (RUX), Best Available Therapy (BAT)
- Where
- 103 sites in Australia, Austria and 20 more
- Volunteers
- 310 people
- Sponsor
- Novartis Pharmaceuticals
Hepatocellular Carcinoma
A Study of MG4101 (Allogeneic Natural Killer Cell) for Intermediate-stage of Hepatocellular Carcinoma
The propose of this study is evaluate the safety and efficacy of MG4101 (allogeneic Natural killer cells) in patients with hepatocellular carcinoma (HCC) after transarterial chemoembolization (TACE).
- Trial name
- NCT02854839
- Testing
- MG4101
- Where
- 6 sites in South Korea
- Volunteers
- 78 people
- Sponsor
- GC Cell Corporation
Muscular Dystrophies, Muscular Dystrophy, Duchenne
A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy
HOPE-3 is a two cohort, Phase 3, multi-center, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of a cell therapy called deramiocel (CAP-1002) in study participants with Duchenne…
- Conditions
- Muscular Dystrophies, Muscular Dystrophy, Duchenne, Muscular Disorders, Atrophic, Muscular Diseases
- Trial name
- HOPE-3 (NCT05126758)
- Testing
- Deramiocel (CAP-1002)
- Where
- 20 sites in United States
- Volunteers
- 106 people
- Sponsor
- Capricor Inc.
Progressive Multiple Sclerosis (PMS), Neuromyelitis Optica
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune Disease
This is a single-arm, open-label, multicenter, ascending dose Phase 1/2 trial evaluating the safety and preliminary efficacy of CTX112 in adult participants with neurological autoimmune diseases (AIDs), including Progressive…
- Conditions
- Progressive Multiple Sclerosis (PMS), Neuromyelitis Optica, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Autoimmune Encephalitis
- Trial name
- CRSP-AID-502 (NCT07804004)
- Testing
- CTX112
- Volunteers
- 220 people
- Sponsor
- CRISPR Therapeutics
Tibiotalar Arthrodesis, Subtalar Arthrodesis
Evaluation of Trinity Evolution in Patients Undergoing Foot and Ankle Fusion
The purpose of this study is to utilize Trinity Evolution as a graft source in foot/ankle fusions and to follow the subjects to measure the clinical outcomes and fusion rate.
- Conditions
- Tibiotalar Arthrodesis, Subtalar Arthrodesis, Calcaneocuboid Arthrodesis, Talonavicular Arthrodesis
- Trial name
- TAF (NCT00988338)
- Testing
- Trinity Evolution
- Where
- 10 sites in United States
- Volunteers
- 106 people
- Sponsor
- Orthofix Inc.
Adult Acute Myeloid Leukemia
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
This is a multi-center, randomized, double-blinded, placebo controlled trial.
- Trial name
- MO-TRANS (NCT05429632)
- Testing
- mocravimod
- Where
- 111 sites in United States, Argentina and 12 more
- Volunteers
- 366 people
- Sponsor
- Priothera SAS
Colorectal Cancer, Metastatic Colorectal Adenocarcinoma
Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer
This Phase 1/2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of an allogeneic dual-target chimeric antigen receptor natural killer (CAR-NK) cell product in adults with advanced or metastatic…
- Conditions
- Colorectal Cancer, Metastatic Colorectal Adenocarcinoma, Unresectable Colorectal Cancer
- Trial name
- DUO-CRC-NK-111 (NCT07589517)
- Testing
- EB-DUO-CAR-NK-CEA/GCC, Lymphodepletion
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Beijing Biotech
Myocardial Infarction
Ex Vivo Cultured Bone Marrow Derived Allogenic MSCs in AMI
This clinical trial aims to find out the safety and efficacy of adult mesenchymal stem cells in patients with myocardial infarction.
- Trial name
- NCT00883727
- Testing
- Stem cell, Plasmalyte A
- Where
- 4 sites in India
- Volunteers
- 20 people
- Sponsor
- Stempeutics Research Pvt Ltd
Type 1 Diabetes Mellitus
Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol
In an earlier Phase 1/2 clinical trial using the Edmonton Protocol of steroid free immunosuppression, investigators at University of Illinois at Chicago (UIC) demonstrated the safety of islet preparation, iset transplantation…
- Trial name
- NCT00679042
- Testing
- Islets of Langerhans transplantation
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- CellTrans Inc.
Acute Myeloid Leukemia
RC1012 Injection (Allo-DNT Cells) for the Prevention of Relapse in AML Patients After Allo-HSCT
To evaluate the safety and tolerability of RC1012 injection infusion in AML Patients after Allo-HSCT
- Trial name
- NCT05858814
- Testing
- RC1012 injection (allo-DNT cells)
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Guangdong Ruishun Biotech Co., Ltd
Diabetic Nephropathy Type 2
Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cell Therapy in Diabetic Nephropathy Patients: A Clinical Trial
The goal of this clinical trial is to evaluate the safety and efficacy of a single intra-renal injection of allogeneic umbilical cord-derived mesenchymal stem cells (UC-MSCs) in adults with diabetic nephropathy aged 40 to 65…
- Trial name
- NCT07396155
- Testing
- Umbilical Cord Mesenchymal Stem Cells
- Where
- Indonesia
- Volunteers
- 10 people
- Sponsor
- PT. Prodia Stem Cell Indonesia
Corona Virus Infection, Covid19
Clinical Study for Subjects With COVID-19 Using Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells
This is an interventional new drug clinical trial for a Phase 2 randomized, double-blind, and placebo control study using intravenous injection of allogeneic adipose stem cells (Celltex AdMSCs) for subjects with severe COVID-19.
- Trial name
- AdMSCs (NCT05017298)
- Testing
- Allogeneic adipose-derived stem cells
- Volunteers
- 30 people
- Sponsor
- Celltex Therapeutics Corporation
ANCA-Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM)
FT839 in Autoimmune Diseases
The primary objectives of this trial are to evaluate the safety and tolerability and to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose of FT839 with or without rituximab and/or background therapy and/or…
- Conditions
- ANCA-Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE)
- Trial name
- NCT07800871
- Testing
- FT839
- Where
- United States
- Volunteers
- 446 people
- Sponsor
- Fate Therapeutics
Primary Immunodeficiencies, Inborn Errors of Metabolism
Treosulfan-based Versus Busulfan-based Conditioning in Paediatric Patients With Non-malignant Diseases
The aim of the trial is to describe the safety and efficacy of intravenous (i.v.) Treosulfan compared to the conventional (myeloablative) dose of i.v.
- Conditions
- Primary Immunodeficiencies, Inborn Errors of Metabolism, Haemoglobinopathies, Bone Marrow Failure Syndromes
- Trial name
- NCT02349906
- Testing
- Treosulfan, Busilvex
- Where
- 21 sites in Czechia, Germany and 2 more
- Volunteers
- 106 people
- Sponsor
- medac GmbH